Loading...
Ranolazine, a novel antianginal agent that is thought to block intracellular sodium and calcium overload in cardiac ischemia, was FDA-approved in 2006 for the treatment of chronic angina. In this multinational randomized trial — which was funded by the manufacturer of ranolazine and included company employees on the study team — 6560 patients (mean age, 64) with acute coronary syndromes (ACS [unstable angina or non–ST-elevation myocardial infarction]) were treated acutely with intravenous ranolazine followed by 1000 mg of oral ranolazine or placebo twice daily. Patients also received usual ACS treatment, including percutaneous interventions in 32% and coronary artery bypass surgery in 8%. Median follow-up was approximately 1 year.
There was …